COVID-19 ASSOCIATED COAGULOPATHY IN PATIENTS WITH NEW CORONAVIRUS SARS COV-2 INFECTION
Abstract
Abstract Coronavirus infection (COVID-19), considered an acute infectious disease caused by the SARS-CoV-2 virus, is characterized by activation of the hemostasis system. As a result of this, severe cases can develop coagulopathy. Whether COVID-19 is the direct cause of this condition or whether they occur with the development of an infectious process remains unclear for the time being. The frequency of occurrence of asymptomatic and clinically specific thrombotic, thromboembolic complications in COVID-19 remains uncertain. This condition is largely associated with difficulties in diagnosis. The purpose of the work to study the significance of coagulopathy markers in patients with COVID-19 and their prognostic role in various clinical forms of the disease. This study was a single-center retrospective cohort study. The usual blood tests: the number of leukocytes (WBC), the number of lymphocytes (LYM), the number of mononuclears (MONO), the number of neutrophils (NEU), platelets were performed on blood samples. Coagulation functions (fibrinogen (Factor I), (prothrombin time (PT), activated partial thromboplastin time (APTT), (international normalized ratio (INR) were determined using the MINDRAY BA - 88A analyzer (China). The concentration of D-dimer was determined using the ELISA method using reagent kits for enzyme immunoassay determination of the concentration of D-dimer in blood plasma D-dimer - ELISA-BEST. The concentration of antibodies to IgM IgG phospholipids was determined using the ELISA method.
References
Literature:
Lanzavecchia A. Antigen-specific interaction between T and B cells // Nature. – 1985. – Vol. 314, no. 11. – P. 537–539.
Scaglioni V., Soriano E.R. Are superantigens the cause of cytokine storm and viral sepsis in severe COVID-19? Observations and hypothesis // Scand. J. Immunol. – 2020. – Vol. 92, no. 6. – P. 1–5.
Gorbalenya A.E., et al. The species Severe acute res piratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 // Nat. Microbiol. – 2020. – Vol. 5, no. 4. – P. 536–544.
Encyclopaedia Britannica, Inc. – URL: https:// www.britannica.com (date of viewing: 12.01.2021).
Bosch B.J., et al. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex // J. Virol. – 2003. – Vol. 77, no. 16. – P. 8801–8811.
Lopez L.A., et al. Importance of conserved cysteine residues in the coronavirus envelope protein // J. Virol. – 2008. – Vol. 82, no. 6. – P. 3000–3010.
Schoeman, D. Coronavirus envelope protein: current knowledge // Virol. J. – 2019. – Vol. 16, no. 1. – P. 69.
Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. On-line April 10.
Oblokulov, A.R., Husenova, Z. Z., & Ergashev, M. M. (2021). Procalcitonin as an indicator of antibacterial therapy in covid-19 // Annals of the Romanian Society for Cell Biology, P. -5220-5224.
Williams EJ et al. (2020). Routine measurement of serum procalcitonin allows antibiotics to be safely with held in patients admitted to hospital with SARS-CoV-2 infection. medRxiv. doi. org/10.1101/2020.06.29.20136572.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost JTH. 2020; 18:844–847. doi: 10.1111/jth.14768.
Escher R, Breakey N, Lammle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res.2020; 190:62. doi: 10.1016/j.thromres.2020.04.014.
Hermans C, Lambert C. Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis. J Thromb Haemost. 2020 doi: 10.1111/jth.14845.
Ergashov M.M. (2023) The importance of C-reactive protein, Procalcitonin, and cytokines in determining the prospect of SARS-COV-2-associated pnumonia // Horizon Journal of Humanity and Artificial Intelligence. Volume: 02 Issue: 06 | 2023, ISSN: 2835-3064. P. -167-171.
Goel MS, Diamond SL. Neutrophil cathepsin G promotes prothrombinase and fibrin formation under flow conditions by activating fibrinogen-adherent platelets. J Biol Chem. 2003; 278:9458–9463. doi: 10.1074/jbc.M211956200.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0.
Nahum J, et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19) JAMA Netw. Open. 2020;3: e2010478. doi: 10.1001/jamanetworkopen.2020.10478.
Niyazov G.E., Oblokulov A.R., Pondina A.I. et al. (2020) Clinical and epidemiological characteristics of COVID-19 patients // New Day in Medicine. №4 (32). P. -110-115.
Becker RC. Toward understanding the 2019 Coronavirus and its impact on the heart. J Thromb Thrombolysis. 2020 doi: 10.1007/s11239-020-02107-6.
Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020; 18:1421–1424. doi: 10.1111/jth.14830.
Niyozov G.E., Mukhtarova Sh.A., Ergashov M.M. (2022) Covid-associated coagulopathy in patients with the new coronavirus infections // Journal infectology. Appendix 1, Volume 14, No. 4, 2022. P. – 73-74.
Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020; 382:1708–1720. doi: 10.1056/NEJMoa2002032.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
Эргашов М.М. (2021). Ролъ прокальцитонинового теста в диагностике и лечении COVID – 19 // III Международное книжное издание – Лучший молодой ученый. Ст.40-42.
Облокулов А.Р., Хусенова З.З., Эргашов М.М. (2021) Значение Уровня Прокальцитонина при назначении и мониторинга антибактериальной терапии пациентов с COVID – 19 // Журнал гепато – гастроэнтерологических исследований. Том №1, Специалый выпуск. Cт. -115-117
Хусенова З.З., Облокулов А.Р. Эргашов М.М. (2021) Клинико – эпидемиологическая характеристика пациентов с SARS CоV – 2 инфекцией // Tibbiyotda yangi kun, №2(34/3)202. Cт. – 270-273.
Облокулов А.Р., Нарзиев И.И., Облоқулов А.А., Эргашов М.М., Бадиева Б.М. (2021) Пандемия шароитида фаолят кўрсатган тиббиёт ходимларида юзага келаган рухий ўзгаришлар // “Инфекция, имунология, фармакалогия” научно-практический журнал. №1/2021. Cт. -58-62.
Oblokulov A.R., Kholov U.A., Niyozov G.E., Khusenova Z.Z., Ergashov M.M. (2021) Extrapulmonal manifestations of COVID – 19 // “Infection, immunity and pharmacology –scientific and practical journal - №1/2021. P. - 62-66.
Oblokulov A.R., Oblokulov А.А., Ergashov M.M. (2021) Clinical And Laboratory Criteria for spontaneous Bacterial Peritonitis In Liver Cirrhosis Of Viral Etiology // Central asian journal of medical and natural sciences. P. - 172-177.
Облокулов А.Р., Хусенова З.З., Эргашов М.М. (2021) Значимость уровня прокальцитонина при терапии пациентов с COVID – 19 // ВЕСТНИК ТМА Ташкетской медициской академии, Ст. - 42-43.
Эргашов М.М. (2023) SARS-COV-2 bilan bog’liq pnevmoniya istiqbolini belgilashda C-reaktiv oqsil, prokalsitonin va sitokinlarning ahamiyati // НАУЧНЫЙ ИМПУЛЬС Международный современный научно-практический журнал. Новости образования: Исследование в XXI веке № 10(100), часть 1 мая, ст. - 366-369.
Ergashov M.M. (2023) The importance of C-reactive protein, procalcitonin, and cytokines in determining the prospect of SARS-COV-2-associated pneumonia // Galaxy International Interdisciplinary Research Journal (GIIRJ) ISSN (E): 2347-6915. Vol. 11, Issue 04, April. P.-480-483.
Авдеева М.Г., Облокулов А.Р., Эргашов М.М. (2022) Прокальцитонин как предиктор антибактериальной терапии при Covid-19 // Новый День в Медицине Том 2 (40) 2022. Ст. -323-327.
Облокулов А.Р., Хусенова З.З., Эргашов М.М. (2021) Значимость уровня прокальцитонина при терапии пациентов с COVID – 19 // Новый день в медицина 2(34)3. Ст. 267-270.
Эргашов М.М., Бомомуратова М.Н. (2023) Прокальцитонин – перспективный диагностический маркер для управления антибактериальными терапии при COVID-19 // Лучшие интеллектуальные исследования. Часть-6, Том-1, ст. -89-94.
Эргашов М.М. (2023) Прогностическое значение прокальцитонинина при COVID – 19 // Ta'lim innovatsiyasi va integratsiyasi. 11-son, 3-to’plam, cт. -122-128.
Эргашов М.М. (2023) Биомаркер прокальцитонин как прогностический фактор антибактериальной терапии covid-19 // “O‘zbekistonda fanlararo innovatsiyalar va ilmiy tadqiqotlar” jurnali. ст. - 30-37.
